Ribociclib succinate (CAS No 1374639-75-4) is a small-molecule inhibitor primarily utilized in cancer research specifically targeting cyclin-dependent kinase 4 and 6 (CDK4/6) which are critical for cell cycle progression By inhibiting these kinases Ribociclib succinate effectively arrests the cell cycle in the G1 phase thereby preventing proliferation of cancer cells It is derived from chemical synthesis processes designed for high specificity and potency In vitro studies have demonstrated its activity in the nanomolar range showcasing its efficacy in inhibiting tumor growth The compound is frequently employed in various cell line studies particularly in breast cancer models and is instrumental in preclinical animal studies to explore therapeutic effects and toxicology Ribociclib succinate is also a valuable tool in drug screening assays aimed at identifying potential combinatory treatments Experimental concentrations typically depend on the specific research design